4 completed, 4 unknown, 3 recruiting, 1 enrolling by invitation. 14 Phase 2, 6 Phase 1, 1 Phase 3.
Follow T Cell Lymphoma: new trials by email Literature Review of T Cell Lymphoma trials Research Report on T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation CD7 CAR-T combined with autologous hematopoietic stem cell transplantation - CD7+ Lymphoma, T Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Zhengzhou University | 38 | 2025-09-01 | 2025-08-12 |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol - T Cell Lymphoma, T-cell Lymphoma | Phase 2 | Recruiting | Yale University | 22 | 2024-10-09 | 2026-04-14 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) ACHOP - T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Won Seog Kim | 41 | 2022-07-01 | 2023-10-23 |
| Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma Chidamide combined with BEAM - T Cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 23 | 2022-05-28 | 2022-09-29 |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. HSP-CAR30 - Hodgkin Lymphoma, Adult, T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 30 | 2020-09-29 | 2020-12-04 |
| Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas Brentuximab Vedotin - T Cell Lymphoma | Phase 2 | Withdrawn | University of Kansas Medical Center | 2020-05-29 | 2023-02-03 | |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Tenalisib, Romidepsin - T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Rhizen Pharmaceuticals SA | 33 | 2019-03-12 | 2022-10-28 |
| Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells AUTO CAR T cell therapy - Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma | Phase 2 | Enrolling by invitation | Autolus Limited | 500 | 2018-08-02 | 2026-09-22 |
| Trial of Endostar Combined With CHOPT for T Cell Lymphoma Endostar and CHOPT - T Cell Lymphoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2011-06-01 | 2015-11-04 |
| Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma endostar and CHOP - T Cell Lymphoma | Phase 2 | Unknown | Fudan University | 15 | 2009-08-01 | 2010-09-15 |
| Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Fostamatinib Disodium - T Cell Lymphoma | Phase 2 | Completed | Rigel Pharmaceuticals | 18 | 2009-03-01 | 2016-09-19 |
| HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma HuMax-CD4 - T Cell Lymphoma | Phase 2 / Phase 3 | Completed | Emergent BioSolutions | 21 | 2005-08-01 | 2024-03-18 |
Lymphoma, T-Cell (14) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic, T-Cell (1) · Leukemia, T-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (14) · Immune System Diseases (14) · Immunoproliferative Disorders (14) · Lymphatic Diseases (14) · Lymphoma, Non-Hodgkin (14) · Lymphoproliferative Disorders (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Lymphoma (13) · Hematologic Diseases (4) · Leukemia (2) · Leukemia, Lymphoid (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
endostar protein (2) · Brentuximab Vedotin (1) · CHOEP protocol (1) · Cyclophosphamide (1) · Doxorubicin (1) · EPOCH protocol (1) · Endostatins (1) · Etoposide (1) · Prednisone (1) · Vincristine (1) · fostamatinib (1) · mogamulizumab (1) · romidepsin (1) · tenalisib (1) · zanolimumab (1)
Autolus Limited (1) · CRISPR Therapeutics (1) · Emergent BioSolutions (1) · Essen Biotech (1) · Fudan University (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Rhizen Pharmaceuticals SA (1) · Rigel Pharmaceuticals (1) · Ruijin Hospital (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University of Kansas Medical Center (1) · Won Seog Kim (1) · Yale University (1) · Zhengzhou University (1)
United States (6) · China (5) · Spain (2) · Australia (1) · Canada (1) · South Korea (1) · United Kingdom (1)
Abhay Patki, PhD (1) · Alissa Keegan, MD, PhD (1) · Jeffrey Skolnik, MD (1) · Junning Cao, MD (1) · Sid Ganguly, MD (1) · Tarsheen Sethi, MD (1)